Successful management of imatinib despite alopecia and nail necrosis
| dc.contributor.author | Ergene U. | |
| dc.contributor.author | Ozbalci D. | |
| dc.date.accessioned | 2025-04-10T11:14:09Z | |
| dc.date.available | 2025-04-10T11:14:09Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd. | |
| dc.identifier.DOI-ID | 10.1016/j.transci.2013.01.002 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/50104 | |
| dc.title | Successful management of imatinib despite alopecia and nail necrosis | |
| dc.type | Article |